The Combination of Nilotinib plus Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Affiliation auteurs!!!! Error affiliation !!!!
TitreThe Combination of Nilotinib plus Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.
Type de publicationJournal Article
Year of Publication2019
AuteursNicolini FE, Etienne G, Huguet F, Guerci-Bresler A, Charbonnier A, Escoffre-Barbe M, Dubruille V, Johnson-Ansah H, Legros L, Coiteux V, Cony-Makhoul P, Lenain P, Roy L, Rousselot P, Guyotat D, Ianotto J-C, Gardembas M, Deconinck E, Larosa F, Caillot D, Turlure P, Courby S, Quittet P, Hermet E, Ame S, Lapusan S, Deloire A, Morisset S, Etienne M, Rea D, Dulucq S, Mahon F-X
JournalBLOOD
Volume134
Date PublishedNOV 13
Type of ArticleMeeting Abstract
ISSN0006-4971
DOI10.1182/blood-2019-123674